clinical trials – Medxy AI

Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: Robust Evidence from the Combined TETON-1 and TETON-2 Phase 3 Trials

By MedXY 09/28/2026

Combined analysis of the TETON-1 and TETON-2 trials confirms inhaled treprostinil significantly slows lung function decline, reduces clinical worsening and exacerbations, and improves quality of life in idiopathic pulmonary fibrosis over one year.

news Oncology Public Health

Disparities in Ovarian Cancer Clinical Trial Access Linked to Social Vulnerability: A U.S. County-Level Analysis

By MedXY 09/25/2026

County-level social vulnerability significantly limits ovarian cancer clinical trial availability, underscoring structural inequities and the need for targeted strategies to improve trial access in vulnerable communities.

Diabetes & Endocrinology news Ophthalmology

Satralizumab Demonstrates Promising Efficacy and Safety in Treating Thyroid Eye Disease: Insights from Phase 3 SatraGO-1 and SatraGO-2 Trials

By MedXY 09/12/2026

Phase 3 trials show satralizumab significantly improves proptosis, inflammation, and diplopia in thyroid eye disease with a favorable safety profile, marking a new therapeutic option targeting the IL-6 receptor pathway.

Cardiology Clinical Updates news

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM and Complementary Trials

By MedXY 09/09/2026

Aficamten, a cardiac myosin inhibitor, demonstrated significant improvements in symptoms, diastolic function, and biomarkers in nonobstructive hypertrophic cardiomyopathy across multiple trials, including the pivotal ACACIA-HCM study.

news Respiratory

Defining and Achieving Disease Stability in COPD: Insights from Phase 3 Trials

By MedXY 09/09/2026

This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.

Gastroenterology Internal Medicine news

Navigating Drug-Induced Liver Injury in Clinical Trials: Insights and Updates from FDA Experts

By MedXY 09/07/2026

Drug-Induced Liver Injury (DILI) remains a pivotal challenge in drug development, with evolving drug modalities and clinical trial designs prompting updated regulatory perspectives from FDA specialists.

Clinical Updates news OB/GYN & Women's Health Oncology

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups

By MedXY 08/22/2026

This review contrasts early- and late-phase gynecologic oncology trials, underscoring disparities in trial completion, publication, and racial/ethnic minority enrollment, highlighting the need to improve inclusivity and reporting.

news OB/GYN & Women’s Health Oncology

Enhancing Patient Engagement in Gynecologic Oncology Clinical Trials Through a Pilot Patient Ambassador Program

By MedXY 08/21/2026

A pilot program using former gynecologic oncology trial participants as patient ambassadors improved confidence and perceptions about clinical trials among trial-naïve patients, highlighting a feasible peer-education approach.

news OB/GYN & Women’s Health Oncology

Navigating Challenges in Gynecologic Cancer Trials: Key Factors Behind Non-Completion and Strategies for Improvement

By MedXY 08/09/2026

This study identifies that 30% of gynecologic cancer clinical trials fail to complete, with insufficient patient accrual as the leading cause, highlighting crucial factors like intervention type, initiation year, and geographic variations that affect trial completion rates.

Clinical Updates Dentistry news

Bridging Periodontitis and Clonal Hematopoiesis: Implications for Solid Tumor Metastasis, Clinical Trial Design, and Microbiome Dynamics

By MedXY 07/24/2026

This review synthesizes evidence linking periodontitis-induced inflammation with clonal hematopoiesis, exploring implications for tumor metastasis, trial methodology, and microbiome-host crosstalk.

$CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives$

Clinical Updates news

CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives

By MedXY 07/13/2026

This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.

Clinical Updates news Respiratory

Ivermectin for COVID-19: From Pandemic Controversy to Definitive Futility in the REMAP-CAP and Global Randomized Trials

By MedXY 05/12/2026

A comprehensive evidence-based synthesis of the REMAP-CAP trial and major international RCTs, demonstrating that ivermectin fails to improve clinical outcomes, survival, or organ support requirements in hospitalized and non-hospitalized COVID-19 patients.

news Oncology

Community-Centered Education Improves Clinical Trial Knowledge and Self-Efficacy Among Minoritized Women

By MedXY 04/26/2026

A culturally tailored educational intervention significantly improved clinical trial knowledge and self-efficacy among African American and Hispanic women, highlighting the potential of community partnerships to address disparities in gynecologic cancer research participation.

Neurology news Public Health

Statistical Inconsistency in ALS Trials: How Analysis Methods Skew Treatment Efficacy

By MedXY 04/22/2026

A study reveals significant variability in ALSFRS-R analysis methods across 45 ALS trials, impacting treatment effect estimates and increasing false-positive risks, with implications for clinical decision-making and drug development.

AI Cardiology news

Adaptive AI Transforms Cardiovascular Event Adjudication: New Algorithm Achieves Near-Human Accuracy Across Multiple Endpoints

By MedXY 04/05/2026

Researchers developed and validated ADAPT-CEC, an artificial intelligence algorithm that can adjudicate cardiovascular events across different trial definitions. A hybrid approach combining AI with selective human review achieved 95.6% accuracy and replicated major trial results.

Cardiology Clinical Updates Diabetes & Endocrinology news

Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis

By MedXY 04/01/2026

This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintaining functional capacity and biomarker stability in ATTR-CM patients.

Neurology news

Beyond the Target: Why SBP Trajectories Predict Functional Recovery in Acute Intracerebral Hemorrhage

By MedXY 03/20/2026

A pooled analysis of 11,269 patients from the INTERACT and ATACH-II trials reveals that 24-hour systolic blood pressure trajectories, rather than just single targets, significantly influence functional outcomes after intracerebral hemorrhage, with persistent hypertension linked to the highest risk of disability.

Medical News news Public Health

Bridging the Evidence Gap: African Representation in Global Randomized Controlled Trials (2019–2024)

By MedXY 03/20/2026

This systematic review analyzes the profound underrepresentation of African populations in high-impact clinical trials, revealing a stark disparity in cardiovascular and general medical research that limits the global applicability of evidence-based medicine.

Neurology news

PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial

By MedXY 03/18/2026

The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.

Cardiology news Oncology

Optimized Heart Failure Therapy in Advanced Cancer: Insights from the EMPATICC Trial

By MedXY 03/12/2026

The EMPATICC trial explored heart failure therapy for patients with advanced cancer in palliative care. While it did not meet its primary endpoint for self-care ability due to high mortality, survivors showed improved cardiac biomarkers and well-being, suggesting potential for individualized cardio-oncology interventions.